Core Insights - PetVivo Holdings, Inc. will hold a conference call on November 14, 2025, to discuss its fiscal second quarter results for the period ending September 30, 2025 [1][2] - The company focuses on innovative medical devices and therapeutics for companion animals, leveraging human therapies for efficient treatment [4] - PetVivo has a strong product pipeline, including SPRYNG with OsteoCushion technology and PrecisePRP, both currently available for commercial sale [5] Company Overview - PetVivo Holdings, Inc. operates through its subsidiary PetVivo Animal Health, Inc., specializing in biomedical devices for companion animals [4] - The company aims to bring veterinary medical devices to market faster than more regulated pharmaceuticals, enhancing revenue timelines [4] - PetVivo holds a portfolio of twelve patents and six trade secrets protecting its biomaterials and products [5] Upcoming Events - The conference call will include a presentation by management followed by a Q&A session [2] - Dial-in information for the conference call includes a toll-free number and a specific conference ID and passcode [2] - A replay of the conference call will be available on the company's website [3]

Core Insights - PetVivo Holdings, Inc. has entered into a 10-year exclusive white-label licensing agreement with Digital Landia Holding Corp for the Agentic Pet AI technology, aimed at addressing high client acquisition costs and engaging the growing Gen Z pet parent demographic [1][13]. Industry Overview - The veterinary industry is experiencing a demographic shift, with Gen Z pet parenthood increasing by 43.5% in 2024, making Gen Z and Millennials account for 57% of all pet parents in the U.S. [3][5]. - Traditional marketing strategies in veterinary practices are failing to connect with the tech-savvy Gen Z demographic, which presents a significant opportunity for innovative solutions [5]. Technology and Solutions - The Agentic Pet AI technology can reduce client acquisition costs by 90% to 98%, lowering costs from $50-$150+ per client to just $1.50-$5.00 per targeted outreach [2][9]. - The technology includes a freemium app with nine specialized AI diagnostic agents that track pet health, allowing pet parents to share health data seamlessly with veterinary practices [7][8]. Economic Impact - The partnership is expected to transform client acquisition for veterinary practices, with a case study showing a reduction in acquisition costs from $80-$120 to $3.50 per client, alongside significant time savings in patient history gathering [11][12]. - The overall efficiency of consultations is projected to improve by 20%, with a 30% increase in preventive care visits due to early issue identification through AI [12]. Market Opportunity - PetVivo is entering a $4.9 billion U.S. veterinary AI market with over 30,000 addressable clinics, leveraging existing relationships with more than 1,000 veterinary clinics for immediate distribution [14]. - The company reported a 141% year-over-year growth in Q1 FY2026, with fiscal 2025 revenue reaching $1.13 million, indicating strong market momentum [14]. Strategic Positioning - The exclusive agreement provides PetVivo with a competitive advantage for 10 years, creating multiple revenue streams through B2B subscriptions and lead generation fees [15]. - The dual-platform launch in Q1 2026 is expected to create immediate network effects, enhancing the value proposition for both pet parents and veterinary practices [13].

Core Insights - PetVivo Holdings, Inc. has entered into note conversion agreements with four existing shareholders to convert $2,018,155 of outstanding promissory notes into 3,669,806 shares of common stock, effectively eliminating over $2 million of debt from its balance sheet [1][4] Group 1: Financial Developments - The total outstanding debt consisted of a principal amount of $1,850,000 and accrued interest of $168,155 [1] - The conversion prices of the notes ranged from $0.50 to $0.75 per share [1] - The successful completion of the note conversion strengthens the company's financial position and allows for more resources to be directed towards product commercialization [4] Group 2: Product Information - PetVivo's signature products include SPRYNG with OsteoCushion Technology, an injectable veterinary medical device that aids in managing joint pain and restoring joint mechanics [2][7] - PrecisePRP is a first-in-class, off-the-shelf platelet-rich plasma product designed for intra-articular administration in dogs and horses, providing a consistent dose of 4 billion platelets per vial [3][7] Group 3: Company Overview - PetVivo Holdings, Inc. focuses on the manufacturing, commercialization, and licensing of innovative medical devices and therapeutics for companion animals [6] - The company has a robust pipeline of products protected by twelve patents and six trade secrets [7]

Core Points - PetVivo Holdings, Inc. will hold a conference call on August 14, 2025, to discuss its fiscal first quarter results for the period ending June 30, 2025 [1][2] - The company focuses on innovative medical devices and therapeutics for companion animals, leveraging human therapies for efficient treatment [4] - PetVivo has a strong product pipeline, including SPRYNG with OsteoCushion technology and PrecisePRP, both currently available for commercial sale [5] Company Overview - PetVivo Holdings, Inc. operates through its subsidiary, PetVivo Animal Health, Inc., and is dedicated to the manufacturing, commercialization, and licensing of biomedical devices for animals [4] - The company holds a portfolio of twelve patents and six trade secrets that protect its biomaterials and products [5] Conference Call Details - The conference call will take place at 5:00 p.m. Eastern time, with a toll-free dial-in number provided for participants [2] - A replay of the conference call will be available on the company's website [3]

Core Insights - Digital Landia, in collaboration with PetVivo Holdings and its subsidiary, is set to launch AgenticPet.ai, the first autonomous pet care AI ecosystem, on May 23, 2025, aimed at transforming pet health and wellness through specialized AI agents [1][2] Group 1: Technology and Innovation - AgenticPet.ai utilizes multi-agent technology to create self-learning AI agents that provide insights into pet health, behavior, and nutrition [2][3] - The platform features specialized agents for veterinary diagnostics, behavioral analysis, nutritional advice, emotional wellness, and IoT data integration, enhancing comprehensive pet care [5][4] - The AI agents undergo rigorous digital certification exams to ensure expert-level mastery in various domains related to pet care [3] Group 2: Business Model and Market Strategy - AgenticPet.ai will adopt a tiered pricing structure, including a freemium tier, a premium subscription at $9.95/month, and an elite package at $24.95/month, making the technology accessible to a wide range of pet owners [4][5] - The platform is expected to onboard 100,000 freemium users within six months of launch, with a conservative estimate of a 10% conversion rate to paid subscriptions, potentially generating nearly $2 million in annual recurring revenue [7] Group 3: Strategic Positioning - PetVivo Holdings aims to align its clinically proven therapies with the innovative AI technology of AgenticPet.ai, enhancing its visibility and value in the veterinary care market [8] - The company focuses on leveraging human therapies for companion animals, which allows for a quicker market entry compared to more regulated pharmaceuticals [10]